Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 16/20 | 0.85 |
| ▸ | PSMB1 | P20618 | 10/20 | 0.85 |
| ▸ | PSMB2 | P49721 | 10/20 | 0.85 |
| ▸ | PSMB11 | A5LHX3 | 9/20 | 0.85 |
| ▸ | PSMA7 | O14818 | 9/20 | 0.85 |
| ▸ | PSMA1 | P25786 | 9/20 | 0.85 |
| ▸ | PSMA2 | P25787 | 9/20 | 0.85 |
| ▸ | PSMA3 | P25788 | 9/20 | 0.85 |
| ▸ | PSMA4 | P25789 | 9/20 | 0.85 |
| ▸ | PSMB8 | P28062 | 9/20 | 0.85 |
| ▸ | PSMB9 | P28065 | 9/20 | 0.85 |
| ▸ | PSMA5 | P28066 | 9/20 | 0.85 |
| ▸ | PSMB4 | P28070 | 9/20 | 0.85 |
| ▸ | PSMB6 | P28072 | 9/20 | 0.85 |
| ▸ | PSMB10 | P40306 | 9/20 | 0.85 |
| ▸ | PSMB3 | P49720 | 9/20 | 0.85 |
| ▸ | PSMA6 | P60900 | 9/20 | 0.85 |
| ▸ | PSMA8 | Q8TAA3 | 9/20 | 0.85 |
| ▸ | PSMB7 | Q99436 | 9/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxysalinosporamide A SCHEMBL8170369 | 1.00 | PSMB5 (0.85) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| Hydroxysalinosporamide A SCHEMBL23266050 | 1.00 | PSMB5 (0.85) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| Hydroxysalinosporamide A SCHEMBL6380446 | 1.00 | PSMB5 (0.85) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| Hydroxysalinosporamide A SCHEMBL8170371 | 1.00 | PSMB5 (0.85) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL6383689 | 0.93 | PSMB5 (0.86) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL8178533 | 0.93 | PSMB5 (0.85) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| Fluorosalinosporamide SCHEMBL31187487 | 0.93 | PSMB5 (0.83) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL8178284 | 0.93 | PSMB5 (0.85) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL8183419 | 0.93 | PSMB5 (0.85) | PSMB5PSMB1PSMB2PSMB11PSMA7 | |
| SCHEMBL8126861 | 0.93 | PSMB5 (0.85) | PSMB5PSMB1PSMB2PSMB11PSMA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2631237-A2 | Total synthesis of salinosporamide A and analogs thereof | Nereus Pharmaceuticals, Inc. (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20130012720-A1 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | NEREUS PHAMACEUTICALS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8314251-B2 | Total synthesis of salinosporamide A and analogs thereof | NEREUS PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2013167-B1 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | NEREUS PHARMACEUTICALS INC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-8067616-B2 | Total synthesis of salinosporamide A and analogs thereof | NEREUS PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067616-B2 | Total synthesis of salinosporamide A and analogs thereof | NEREUS PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110269969-A1 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | NEREUS PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-8003802-B2 | Total synthesis of Salinosporamide A and analogs thereof | NEREUS PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003802-B2 | Total synthesis of Salinosporamide A and analogs thereof | NEREUS PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110105762-A1 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | NEREUS PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105762-A1 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | NEREUS PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-7842814-B2 | Total synthesis of salinosporamide A and analogs thereof | NEREUS PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842814-B2 | Total synthesis of salinosporamide A and analogs thereof | NEREUS PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| WO-2009134531-A2 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | NEREUS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090234137-A1 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | NEREUS PHARMACEUTICALS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090234137-A1 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | NEREUS PHARMACEUTICALS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| WO-2007117591-A9 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | NEREUS PHARMACEUTICALS INC (US) | 2008-10-02 | — | — | WO | disclosed |
| US-20070249693-A1 | deprotecting, aldol condensations, cleaving double bonds, deesterifying, alcoholization, oxidation with organometallic, lactonization | NEREUS PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249693-A1 | deprotecting, aldol condensations, cleaving double bonds, deesterifying, alcoholization, oxidation with organometallic, lactonization | NEREUS PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007117591-A2 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | NEREUS PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012720-A1 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | ERG28, CYP51A1, EIF4A2 | PSMB5 2700/4885PSMB1 3493/4885PSMB2 2769/4885 |
| US-20110105762-A1 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | ERG28, CYP51A1, LSS | PSMB5 2109/4885PSMB1 3325/4885PSMB2 2946/4885 |
| US-20070249693-A1 | deprotecting, aldol condensations, cleaving double bonds, deesterifying, alcoholization, oxidation with organometallic, lactonization | ADH1C, ADH1A, ADH5 | PSMB5 2681/4885PSMB1 3821/4885PSMB2 3721/4885 |
| US-20090234137-A1 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | ERG28, CYP51A1, EIF4A2 | PSMB5 2700/4885PSMB1 3493/4885PSMB2 2769/4885 |
| US-20110269969-A1 | TOTAL SYNTHESIS OF SALINOSPORAMIDE A AND ANALOGS THEREOF | ERG28, CYP51A1, EIF4A2 | PSMB5 2700/4885PSMB1 3493/4885PSMB2 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.